SHSifei Han

Sifei Han

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sifei Han has a total of 95 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • An oral allopregnanolone prodrug bypasses liver metabolism via lymphatic transport enabling bioavailability in animals and humans

    by Jamie S. Simpson, Tim Quach, Sifei Han, Luojuan Hu, Natalie L. Trevaskis, Nathania J. Leong, Garima Sharma, Dan Zheng, Steven M. Paul, Christopher J. H. Porter, et al.

    Allopregnanolone, an endogenous neuroactive steroid, has antidepressant and anxiolytic activity but poor oral bioavailability because of substantial first-pass hepatic metabolism. To address the broader challenge of oral bioavailability across clinically validated therapeutics in neuropsychiatry, we developed a lymphatic-targeting prodrug technology platform called Glyph in which a drug of interest is conjugated to a dietary lipid molecule using specifically designed linker chemistry to shift drug absorption to the gut lymphatic system, thus bypassing hepatic metabolism. A series of allopregnanolone prodrugs with different functional linker elements was designed, synthesized, and screened in vitro for gut lymphatic transport and plasma release. Multiple prodrugs achieved therapeutically relevant plasma allopregnanolone concentrations after oral dosing in small- and large-animal models consistent with results from in vitro screening. A triglyceride-mimetic prodrug, GlyphAllo (SPT-300 or Glyph Allopregnanolone), was selected and tested in a phase 1/2a clinical trial (NCT05129865) in 189 healthy participants. Single- and multiple-ascending oral dosing showed that this prodrug could generate therapeutically relevant plasma concentrations in trial participants. GlyphAllo was generally well tolerated and resulted in delivery of allopregnanolone to the systemic circulation and exposure-dependent pharmacodynamic effects via GABA A (γ-aminobutyric acid type A) receptor positive allosteric modulation. In a subsequent randomized, double-blind, placebo-controlled phase 2a trial using the Trier Social Stress Test (TSST), a validated clinical test for anxiety, GlyphAllo was reported to reduce the salivary cortisol stress response compared with placebo at all post-TSST time points. Collectively, these data support further investigation of GlyphAllo for treating mood and anxiety disorders.


  • Subcutaneously administered anti-PD-(L)1 antibodies are predominantly absorbed via the lymphatic system, resulting in high drug exposure to draining lymph nodes

    by Xiaoxuan Fei, Junyi Pei, Simin Yan, Weihong Ge, Li Li, Jianjun Zou, Huimin Zhang, Lie Sun, Sifei Han, Luojuan Hu


  • Optimizing Triglyceride Prodrugs of a Model Immunomodulator: Conjugation through the Phenol of Mycophenolic Acid (MPA) Markedly Promotes Lymphatic Drug Transport

    by Luojuan Hu, Tim Quach, Dan Zheng, Nathania J. Leong, Garima Sharma, Shea Fern Lim, Daniel Bonner, Natalie L. Trevaskis, Jamie S. Simpson, Sifei Han, et al.

    Enhanced transport of immunomodulators via the lymphatics may increase drug exposure to therapeutic targets in the immune system. Our laboratory has demonstrated a triglyceride (TG) mimetic prodrug approach to enhance the lymphatic delivery of a model immunomodulator, mycophenolic acid (MPA), via conjugation of the carboxylic acid of MPA to a TG backbone, where the so formed prodrug is able to incorporate into intestinal TG deacylation-reacylation and lymph lipoprotein transport pathways (up to 37% of the administered dose being absorbed via the lymphatics). In the current study, another conjugation site in the molecule of MPA, i.e., the phenolic group, was explored for its potential to optimize the lymphatic transport profiles of TG mimetic prodrugs of MPA. This offers an unusual opportunity to directly compare the utility of TG prodrugs formed via conjugation to an acid versus a phenol in the same core molecule, which has not been examined previously for other parent drugs. A series of linkers were examined to connect the MPA moiety with the TG backbone. Lymphatic transport was assessed in mesenteric lymph duct cannulated rats, and drug exposure in the mesenteric lymph nodes was examined following oral administration to mice. Compared to the data observed previously for MPA prodrugs conjugated via the carboxylic acid, the new phenol-conjugated prodrugs showed clearly different profiles in terms of the linker chemistry. Prodrugs with shorter chain alkyl spacers (e.g., C4 and C6) supported minimal lymphatic transport (<3% of the dose recovered in lymph). When the chain lengths were longer (≥C10), the prodrugs demonstrated much higher potential for lymphatic transport (up to approximately 55% of dose). Although effectively promoting lymphatic transport, TG mimetic prodrugs with alkyl chain linkers did not necessarily result in marked increases in the exposure of MPA in the mesenteric lymph nodes in mice. Subsequently a number of self-immolative linkers conjugated via the phenol were explored to promote MPA liberation from the prodrugs, and these constructs demonstrated enhanced lymph node exposure. This study provides further insight into structure-lymphatic transport relationships for lymph-directing lipid mimetic prodrugs.


  • Intestinal Lymphatic Biology, Drug Delivery, and Therapeutics: Current Status and Future Directions

    by Sanjeevini Babu Reddiar, Yining Xie, Mohammad Abdallah, Sifei Han, Luojuan Hu, Orlagh M. Feeney, Gracia Gracia, Abel Anshabo, Zijun Lu, Muhammad Asim Farooq, et al.

    Historically, the intestinal lymphatics were considered passive conduits for fluids, immune cells, dietary lipids, lipid soluble vitamins and lipophilic drugs. Studies of intestinal lymphatic drug delivery in the late 20th century focussed primarily on the drug physicochemical properties, especially high lipophilicity, that resulted in intestinal lymphatic transport. More recent discoveries have changed our traditional view by demonstrating that the lymphatics are active, plastic and tissue-specific players in a range of biological and pathological processes, including within the intestine. These findings have, in turn, inspired exploration of lymph-specific therapies for a range of diseases, as well as the development of more sophisticated strategies to actively deliver drugs or vaccines to the intestinal lymph, including a range of nanotechnologies, lipid prodrugs and lipid-conjugated materials that 9hitchhike9 on lymphatic transport pathways. With the increasing development of novel biological therapeutics there has been interest in whether these novel therapeutics are absorbed and transported through intestinal lymph after oral administration. Here we review the current state of understanding of the anatomy and physiology of the gastrointestinal lymphatic system in health and disease, with a focus on aspects relevant to drug delivery. We summarise the current state-of-the-art approaches to deliver drugs and quantify their uptake into the intestinal lymphatic system. Finally, and excitingly, we discuss recent examples of significant pharmacokinetic and therapeutic benefits achieved via intestinal lymphatic drug delivery. We also propose approaches to advance the development and clinical application of intestinal lymphatic delivery strategies into the future. Significance Statement This comprehensive review details understanding of the anatomy and physiology of the intestinal lymphatic system in health and disease, with a focus on aspects relevant to drug delivery. It highlights current state-of-the-art approaches to deliver drugs to the intestinal lymphatics and the shift toward the use of these strategies to achieve pharmacokinetic and therapeutic benefits for patients.


  • Lymphatic Uptake of a Highly Lipophilic Protease Inhibitor Prodrug from a Lipid-Based Formulation is Limited by Instability in the Intestine

    by Yining Xie, Zijun Lu, Ian K. Styles, Sanjeevini Babu Reddiar, Anthony R.J. Phillips, John A. Windsor, Christopher J.H. Porter, Sifei Han, Natalie L. Trevaskis


  • Increasing Linker Chain Length and Intestinal Stability Enhances Lymphatic Transport and Lymph Node Exposure of Triglyceride Mimetic Prodrugs of a Model Immunomodulator Mycophenolic Acid

    by Sifei Han, Tim Quach, Luojuan Hu, Shea Fern Lim, Dan Zheng, Nathania J. Leong, Garima Sharma, Daniel Bonner, Jamie S. Simpson, Natalie L. Trevaskis, et al.

    Targeted delivery of immunomodulators to the lymphatic system has the potential to enhance therapeutic efficacy by increasing colocalization of drugs with immune targets such as lymphocytes. A triglyceride (TG)-mimetic prodrug strategy has been recently shown to enhance the lymphatic delivery of a model immunomodulator, mycophenolic acid (MPA), via incorporation into the intestinal TG deacylation-reacylation and lymph lipoprotein transport pathways. In the current study, a series of structurally related TG prodrugs of MPA were examined to optimize structure-lymphatic transport relationships for lymph-directing lipid-mimetic prodrugs. MPA was conjugated to the sn-2 position of the glyceride backbone of the prodrugs using linkers of different chain length (5-21 carbons) and the effect of methyl substitutions at the alpha and/or beta carbons to the glyceride end of the linker was examined. Lymphatic transport was assessed in mesenteric lymph duct cannulated rats, and drug exposure in lymph nodes was examined following oral administration to mice. Prodrug stability in simulated intestinal digestive fluid was also evaluated. Prodrugs with straight chain linkers were relatively unstable in simulated intestinal fluid; however, co-administration of lipase inhibitors (JZL184 and orlistat) was able to reduce instability and increase lymphatic transport (2-fold for a prodrug with a 6-carbon spacer, i.e., MPA-C6-TG). Methyl substitutions to the chain resulted in similar trends in improving intestinal stability and lymphatic transport. Medium- to long-chain spacers (C12, C15) between MPA and the glyceride backbone were most effective in promoting lymphatic transport, consistent with increases in lipophilicity. In contrast, short-chain (C6-C10) linkers appeared to be too unstable in the intestine and insufficiently lipophilic to associate with lymph lipid transport pathways, while very long-chain (C18, C21) linkers were also not preferred, likely as a result of increases in molecular weight reducing solubility or permeability. In addition to more effectively promoting drug transport into mesenteric lymph, TG-mimetic prodrugs based on a C12 linker resulted in marked increases (>40 fold) in the exposure of MPA in the mesenteric lymph nodes in mice when compared to administration of MPA alone, suggesting that optimizing prodrug design has the potential to provide benefit in targeting and modulating immune cells.


  • Open Access

    Intestinal Lymph Flow, and Lipid and Drug Transport Scale Allometrically From Pre-clinical Species to Humans

    by Natalie L. Trevaskis, Given Lee, Alistair Escott, Kian Liun Phang, Jiwon Hong, Enyuan Cao, Kasiram Katneni, Susan A. Charman, Sifei Han, William N. Charman, et al.

    The intestinal lymphatic system transports fluid, immune cells, dietary lipids, and highly lipophilic drugs from the intestine to the systemic circulation. These transport functions are important to health and when dysregulated contribute to pathology. This has generated significant interest in approaches to deliver drugs to the lymphatics. Most of the current understanding of intestinal lymph flow, and lymphatic lipid and drug transport rates, comes from in vitro studies and in vivo animal studies. In contrast, intestinal lymphatic transport studies in human subjects have been limited. Recently, three surgical patients had cannulation of the thoracic lymph duct for collection of lymph before and during a stepwise increase in enteral feed rate. We compared these data to studies where we previously enterally administered controlled quantities of lipid and the lipophilic drug halofantrine to mice, rats and dogs and collected lymph and blood (plasma). The collected lymph was analyzed to compare lymph flow rate, triglyceride (TG) and drug transport rates, and plasma was analyzed for drug concentrations, as a function of enteral lipid dose across species. Lymph flow rate, TG and drug transport increased with lipid administration in all species tested, and scaled allometrically according to the equation A = aME where A is the lymph transport parameter, M is animal body mass, a is constant and E is the allometric exponent. For lymph flow rate and TG transport, the allometric exponents were 0.84–0.94 and 0.80–0.96, respectively. Accordingly, weight normalized lymph flow and TG mass transport were generally lower in larger compared to smaller species. In comparison, mass transport of drug via lymph increased in a greater than proportional manner with species body mass with an exponent of ∼1.3. The supra-proportional increase in lymphatic drug transport with species body mass appeared to be due to increased partitioning of drug into lymph rather than blood following absorption. Overall, this study proposes that intestinal lymphatic flow, and lymphatic lipid and drug transport in humans is most similar to species with higher body mass such as dogs and underestimated by studies in rodents. Notably, lymph flow and lipid transport in humans can be predicted from animal data via allometric scaling suggesting the potential for similar relationships with drug transport.


  • Lymphatic Uptake of Liposomes after Intraperitoneal Administration Primarily Occurs via the Diaphragmatic Lymphatics and is Dependent on Liposome Surface Properties

    by Given Lee, Sifei Han, Iasmin Inocencio, Enyuan Cao, Jiwon Hong, Anthony R. J. Phillips, John A. Windsor, Christopher J. H. Porter, Natalie L. Trevaskis

    Drugs are commonly administered via the intraperitoneal (IP) route to treat localised infections and cancers in patients, and to test drug efficacy and toxicity in pre-clinical studies. Despite this, there remain large gaps in our understanding of drug absorption routes (lymph vs. blood) and pharmacokinetics following IP administration. This is particularly true when drugs are administered in complex delivery systems such as liposomes which are the main marketed formulation for several drugs that are administered IP. This study investigated the impact of liposome surface properties (charge and PEGylation) on absorption into lymph and blood, and lymphatic disposition patterns, following IP administration. To achieve this, stable 100-150 nm diameter 3H-dipalmitoyl-phosphatidylcholine (DPPC) and 14C-sucrose radiolabelled liposomes with negative, neutral, or positive surface charge, or a PEGylated surface, were prepared and IP administered to rats. Radiolabel concentrations were measured in lymph, blood and lymph nodes. Lymph was collected from the thoracic lymph duct at either the abdomen (ABD) or the jugular-subclavian junction (JSJ). The lymphatic recovery of the radiolabels was substantially lower after administration in positively charged compared to the neutral, negative or PEGylated liposomes. Radiolabel recovery was substantially greater (up to 18-fold) in thoracic lymph collected at the JSJ when compared to the ABD suggesting that liposomes entered the lymphatics at the diaphragm. Consistent with this, the concentration of the liposome labels was substantially higher (up to 7-fold) in mediastinal than mesenteric lymph nodes. Overall, this study shows how the peritoneal absorption and lymphatic disposition of IP administered drugs can be manipulated through careful selection of the drug delivery system and may thus be optimised to treat localised conditions such as cancers, infections, inflammatory diseases and acute and critical illness.


  • Open Access

    Enhancing the Oral Absorption of Kinase Inhibitors Using Lipophilic Salts and Lipid-Based Formulations

    by Hywel D. Williams, Leigh Ford, Sifei Han, Kristian J. Tangso, Shea Fern Lim, David M. Shackleford, David T. Vodak, Hassan Benameur, Colin W. Pouton, Peter J. Scammells, et al.

    The absolute bioavailability of many small molecule kinase inhibitors (smKIs) is low. The reasons for low bioavailability are multifaceted and include constraints due to first pass metabolism and poor absorption. For smKIs where absorption limits oral bioavailability, low aqueous solubility and high lipophilicity, often in combination with high-dose requirements have been implicated in low and variable absorption, food-effects and absorption-related drug-drug interactions. The current study has evaluated whether preparation of smKIs as lipophilic salts/ionic liquids in combination with co-administration with lipid-based formulations is able to enhance absorption for examples of this compound class. Lipophilic (docusate) salt forms of erlotinib, gefitinib, ceritinib and cabozantinib (as example smKIs demonstrating low aqueous solubility and high lipophilicity) were prepared, and isolated as workable powder solids. In each case, the lipophilic salt exhibited high and significantly enhanced solubility in lipidic excipients (>100 mg/g) when compared to the free base or commercial salt form. Isolation as the lipophilic salt facilitated smKI loading in model lipid formulations at high concentration, increased in vitro solubilization at gastric and intestinal pH and in some cases increased oral absorption (~2-fold for cabozantinib formulations in rats). Application of a lipophilic salt approach can therefore facilitate the use of lipid-based formulations for examples of the smKI compound class where low solubility limits absorption and is a risk factor for increased variability due to food-effects.